English, Article edition: Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcitabine in Combination With Best Supportive Care Gunnel Ragnarsont Tennvall; Nils Wilking

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119625
Physical Description
  • article
Language
  • English

Edition details

Title
  • Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcitabine in Combination With Best Supportive Care
Author
  • Gunnel Ragnarsont Tennvall
  • Nils Wilking
Physical Description
  • article
Notes
  • Objective. Patients with pancreatic cancer have only short survival after diagnosis, irrespective of treatment. The aim of this study was to perform a health economic evaluation of present standard treatment (in most cases, palliative treatment in combination with best supportive care) versus palliative treatment with gemcitabine in combination with best supportive care in patients with locally advanced pancreatic carcinoma. Design. The use of resources and associated costs according to present treatment practice were estimated and calculated retrospectively. Costs were calculated from diagnosis until death. Actual costs and treatment effects for the patient population were compared with expected treatment costs for the same population if they additionally received gemcitabine. Setting. This economic analysis is based on a hypothetical comparison and was performed from a societal point of view. Patients and participants. The study population consisted of all patients diagnosed with pancreatic cancer during the year April 1994 to March 1995 and resident in Stockholm County, Sweden. After exclusions, 184 patients were included in the economic analysis. Interventions. The effects of gemcitabine treatment on survival and disease-related symptoms were extrapolated from the results of a recent randomised clinical trial in North America. Main outcome measures and results. The estimated additional costs for chemotherapy, treatment of adverse effects and in- and outpatient care associated with gemcitabine treatment were approximately 132 000 Swedish kronor (SEK) per life-year gained. This result is comparable with costs per life-year gained for other accepted treatments, for example those of home dialysis and kidney transplants for chronic renal failure. Conclusions. Treatment with gemcitabine in patients with pancreatic cancer may be a cost-effective alternative, but the results need to be confirmed in future randomised trials.
  • Pharmacoeconomics, Pancreatic-cancer, Gemcitabine, Pancreatic-surgery, Antineoplastics, Cost-effectiveness, Mortality
  • RePEc:wkh:phecon:v:15:y:1999:i:4:p:377-384
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment